1. Home
  2. SPRO vs BW Comparison

SPRO vs BW Comparison

Compare SPRO & BW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SPRO
  • BW
  • Stock Information
  • Founded
  • SPRO 2013
  • BW 1867
  • Country
  • SPRO United States
  • BW United States
  • Employees
  • SPRO N/A
  • BW N/A
  • Industry
  • SPRO Biotechnology: Pharmaceutical Preparations
  • BW Building Products
  • Sector
  • SPRO Health Care
  • BW Industrials
  • Exchange
  • SPRO Nasdaq
  • BW Nasdaq
  • Market Cap
  • SPRO 110.9M
  • BW 119.1M
  • IPO Year
  • SPRO 2017
  • BW N/A
  • Fundamental
  • Price
  • SPRO $2.13
  • BW $3.24
  • Analyst Decision
  • SPRO Buy
  • BW Strong Buy
  • Analyst Count
  • SPRO 4
  • BW 1
  • Target Price
  • SPRO $5.00
  • BW $5.00
  • AVG Volume (30 Days)
  • SPRO 308.6K
  • BW 3.4M
  • Earning Date
  • SPRO 11-13-2025
  • BW 11-11-2025
  • Dividend Yield
  • SPRO N/A
  • BW N/A
  • EPS Growth
  • SPRO N/A
  • BW N/A
  • EPS
  • SPRO N/A
  • BW N/A
  • Revenue
  • SPRO $48,576,000.00
  • BW $724,905,000.00
  • Revenue This Year
  • SPRO N/A
  • BW N/A
  • Revenue Next Year
  • SPRO N/A
  • BW $8.02
  • P/E Ratio
  • SPRO N/A
  • BW N/A
  • Revenue Growth
  • SPRO N/A
  • BW 48.90
  • 52 Week Low
  • SPRO $0.51
  • BW $0.22
  • 52 Week High
  • SPRO $3.22
  • BW $3.55
  • Technical
  • Relative Strength Index (RSI)
  • SPRO 60.07
  • BW 61.39
  • Support Level
  • SPRO $1.84
  • BW $2.70
  • Resistance Level
  • SPRO $2.05
  • BW $3.47
  • Average True Range (ATR)
  • SPRO 0.08
  • BW 0.35
  • MACD
  • SPRO 0.03
  • BW -0.05
  • Stochastic Oscillator
  • SPRO 85.71
  • BW 60.32

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

About BW Babcock & Wilcox Enterprises Inc.

Babcock & Wilcox Enterprises Inc is a power generation equipment supplier and servicing company that operates in three segments: B&W Renewable, B&W Environmental, and B&W Thermal. B&W Thermal, focuses on steam generation products and solutions for plants in the power generation, oil, and gas, and industrial sectors, generates the majority of the company's revenue. B&W Renewable focuses on sustainable power and heat generation while B&W Environmental focuses on emissions control. The company's customer base spans the industrial, electrical utility, and municipal industries located predominantly in the United States, Canada, Denmark, the United Kingdom, and other regions. Business in the U.S. contributes the vast majority of its revenue.

Share on Social Networks: